{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:17:35Z","timestamp":1777897055544,"version":"3.51.4"},"reference-count":53,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Buprenorphine is the most frequently prescribed medication for treating substance use disorders in the United States, but few studies have evaluated the structure of treatment delivered in real-world settings. The purpose of this study is to investigate adherence to current buprenorphine treatment guidelines using administrative data for Massachusetts Medicaid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified buprenorphine treatment episodes beginning in 2009 through pharmacy claims. We then used service claims to identify treatment-related physician, behavioral, and laboratory services received in the induction, stabilization, and maintenance phases of these treatment episodes. Rates of service utilization were compared with those recommended in treatment guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3674 treatment episodes met inclusion criteria, representing 3005 unique Medicaid beneficiaries. Liver enzymes were tested in 47.3% of episodes, but testing for hepatitis C (23.2%), hepatitis B (19.6%), and human immunodeficiency virus (HIV; 13.7%) was less frequent. Adherence to recommended physician visit frequency was 37.6% during induction, 39.7% during stabilization, and 51.2% during maintenance. For behavioral care, adherence rates were 40.0% during induction, 41.2% during stabilization, and 41.0% during maintenance. Rates of toxicology testing met or exceeded recommendations in just over 60% of episodes in the induction (61.1%), stabilization (62.1%), and maintenance (61.4%) phases. Although rates varied by treatment phase, substantial proportions of episodes showed no evidence of physician visits (27.2\u201342.8%), behavioral care (44.3\u201360.0%), and toxicology screening (25.3\u201339.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that there is significant variability in the structure of buprenorphine treatment provided to Massachusetts Medicaid beneficiaries, and that half or less of episodes include physician and behavioral visits at recommended frequencies. The use of administrative data for this type of analysis is limited by the potential for missing or inaccurate data. More research is needed to establish the levels of services most closely associated with positive outcomes to help guide providers in offering the highest-quality care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2014.991469","type":"journal-article","created":{"date-parts":[[2015,2,23]],"date-time":"2015-02-23T13:29:56Z","timestamp":1424698196000},"page":"174-182","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program"],"prefix":"10.1177","volume":"36","author":[{"given":"Jeffrey D.","family":"Baxter","sequence":"first","affiliation":[{"name":"Center for Health Policy and Research, University of Massachusetts Medical School, Shrewsbury, Massachusetts, USA"},{"name":"Department of Family Medicine and Community Health, University of Massachusetts Medical School, Worcester, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Research, University of Massachusetts Medical School, Shrewsbury, Massachusetts, USA"},{"name":"Department of Family Medicine and Community Health, University of Massachusetts Medical School, Worcester, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihail","family":"Samnaliev","sequence":"additional","affiliation":[{"name":"Division of General Pediatrics, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Aweh","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Research, University of Massachusetts Medical School, Shrewsbury, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"O'Connell","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Research, University of Massachusetts Medical School, Shrewsbury, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,4,1]]},"reference":[{"key":"bibr1-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.541"},{"key":"bibr2-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.12.008"},{"key":"bibr3-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0228.x"},{"key":"bibr4-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1370\/afm.665"},{"key":"bibr5-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1080\/10550490701860971"},{"key":"bibr6-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1300\/J069v26n02_03"},{"key":"bibr7-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.013"},{"key":"bibr8-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00194-6"},{"key":"bibr9-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2009.05.003"},{"key":"bibr10-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2013.07.007"},{"key":"bibr11-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.96912676.x"},{"key":"bibr12-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00214-3"},{"key":"bibr13-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523010-00007"},{"key":"bibr14-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.3310\/hta11090"},{"key":"bibr15-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00169-8"},{"key":"bibr16-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1962-8"},{"key":"bibr17-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2010.0532"},{"key":"bibr18-08897077.2014.991469","unstructured":"Centers for Disease Control and Prevention (CDC). Buprenorphine prescribing practices and exposures reported to a poison center\u2014Utah, 2002\u20132011. MMWR Morb Mort Wkly Rep. 2012;61:997\u20131001."},{"key":"bibr19-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.10.016"},{"key":"bibr20-08897077.2014.991469","unstructured":"Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. Rockville: MD: Substance Abuse and Mental Health Services Administration; 2004. DHHS Publication No. (SMA) 04-3939. Available at: http:\/\/buprenorphine.samhsa.gov\/Bup_Guidelines.pdf. Accessed September 1, 2009."},{"key":"bibr21-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1081\/JA-200034589"},{"key":"bibr22-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12201"},{"key":"bibr23-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00048"},{"key":"bibr24-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00055"},{"key":"bibr25-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021308007343"},{"key":"bibr26-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31819c95aa"},{"key":"bibr27-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(01)00208-2"},{"key":"bibr28-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(02)00303-3"},{"key":"bibr29-08897077.2014.991469","first-page":"19","volume":"29","author":"Garnick DW","year":"2006","journal-title":"Alcohol Res Health."},{"key":"bibr30-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2008.06.008"},{"key":"bibr31-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2010.10400550"},{"key":"bibr32-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.08.005"},{"key":"bibr33-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.01.004"},{"key":"bibr34-08897077.2014.991469","first-page":"29","volume":"21","author":"Kronick R","year":"2000","journal-title":"Health Care Financing Rev."},{"key":"bibr35-08897077.2014.991469","unstructured":"American Medical Association. CPT\u2014Current Procedural Terminology. Available at: http:\/\/www.ama-assn.org\/ama\/pub\/physician-resources\/solutions-managing-your-practice\/coding-billing-insurance\/cpt.page? Accessed May 6, 2015."},{"key":"bibr36-08897077.2014.991469","unstructured":"Centers for Medicare and Medicaid Services. The Healthcare Common Procedure Coding Set (HCPCS). Available at: http:\/\/www.ama-assn.org\/ama\/pub\/physician-resources\/solutions-managing-your-practice\/coding-billing-insurance\/cpt.page? Accessed May 6, 2015."},{"key":"bibr37-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0866-8"},{"key":"bibr38-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2009.08.001"},{"key":"bibr39-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2010.01.001"},{"key":"bibr40-08897077.2014.991469","unstructured":"Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mort Wkly Rep. 2006;55(RR14):1\u201317."},{"key":"bibr41-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2012.677753"},{"key":"bibr42-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0686-x"},{"key":"bibr43-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2008.59.8.909"},{"key":"bibr44-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00032-2"},{"key":"bibr45-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.01.004"},{"key":"bibr46-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1111\/add.12266"},{"key":"bibr47-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.121"},{"issue":"74","key":"bibr48-08897077.2014.991469","first-page":"e11","volume":"126","author":"Fiellin DA","year":"2013","journal-title":"Am J Med."},{"key":"bibr49-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055255"},{"key":"bibr50-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.9059"},{"key":"bibr51-08897077.2014.991469","unstructured":"The Avisa Group and the Treatment Research Institute (TRI). Advancing access to addiction medication: implications for opioid treatment. Available at: http:\/\/www.asam.org\/docs\/advocacy\/Implications-for-Opioid-Addiction-Treatment. Published 2013. Accessed July 17, 2013."},{"key":"bibr52-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2007.03.001"},{"key":"bibr53-08897077.2014.991469","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.012"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2014.991469","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2014.991469","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2014.991469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:45:48Z","timestamp":1777625148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2014.991469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1080\/08897077.2014.991469"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2014.991469","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}